Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial by Weber, J, Del Vecchio, M, Mandala, M, Gogas, H, Arance, A, Dalle, S, Cowey, C, Schenker, M, Grob, J, Chiarion-Sileni, V, Marquez-Rodas, I, Butler, M, Maio, M, Middleton, M, Tang, T, Saci, A, De Pril, V, Lobo, M, Larkin, J, Ascierto, P